English High Court upholds Sequenom patent for prenatal test
18-06-2019
Doro Guzenda / Shutterstock.com
A pressing need for more non-invasive prenatal tests is leading to increasing IP activity and commercial interest, say Fran Salisbury and Alice Jefferies of Mewburn Ellis.
A pressing need for more non-invasive prenatal tests is leading to increasing IP activity and commercial interest, say Fran Salisbury and Alice Jefferies of Mewburn Ellis.
For many expectant parents, pregnancy is a time of excitement, yet it can also be riddled with uncertainty. Unexpected complications affect one in five pregnancies, and only one in five pregnancy complications can be predicted by current clinical assessments. To further complicate the situation, many of the tests currently used in the clinic are invasive, risky, and fraught with bias.
Thus, there is a pressing need for a more comprehensive pathophysiological understanding of pregnancy (for both mother and baby) and more rigorous, yet safe, diagnostic procedures.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
non-invasive prenatal tests, patents
